PKO Investment Management Joint Stock Co Buys Shares of 5,500 Charles River Laboratories International, Inc. (NYSE:CRL)

PKO Investment Management Joint Stock Co purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,500 shares of the medical research company's stock, valued at approximately $828,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its stake in shares of Charles River Laboratories International by 61.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock worth $84,000 after purchasing an additional 175 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in Charles River Laboratories International in the 4th quarter worth about $335,000. V Square Quantitative Management LLC boosted its holdings in Charles River Laboratories International by 12.6% in the 4th quarter. V Square Quantitative Management LLC now owns 1,084 shares of the medical research company's stock worth $200,000 after buying an additional 121 shares during the last quarter. Baillie Gifford & Co. increased its stake in Charles River Laboratories International by 10.0% during the 4th quarter. Baillie Gifford & Co. now owns 75,411 shares of the medical research company's stock worth $13,921,000 after buying an additional 6,826 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its holdings in shares of Charles River Laboratories International by 1.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company's stock valued at $3,522,000 after acquiring an additional 315 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CRL shares. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a report on Thursday, May 8th. Finally, Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Stock Performance

NYSE CRL traded up $2.08 during trading hours on Friday, hitting $147.37. The company had a trading volume of 1,542,754 shares, compared to its average volume of 1,010,136. The business has a 50 day moving average of $130.79 and a 200-day moving average of $155.92. The company has a market cap of $7.24 billion, a PE ratio of -226.73, a price-to-earnings-growth ratio of 4.48 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business's revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.27 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).